Celator Pharmaceuticals announced that it has expanded its research agreement with Cephalon, Inc.. The research agreement provides for the utilization of Celator's proprietary technology in an ongoing drug development and life-cycle management programme at Cephalon.
"We are pleased that work with this research programme has led to its expansion and excited that a global biopharmaceutical company of Cephalon's stature is increasingly interested in the potential of our technologies," said Scott Jackson, chief executive officer, Celator Pharmaceuticals. "Because our nano-scale delivery platforms have already been shown to improve the pharmacokinetics and antitumour activity of several cancer therapies, we are eager to collaborate with companies like Cephalon with growing oncology portfolios and an established commitment to improving treatment outcomes."
Celator is advancing a number of its own programs based on the Company's proprietary nano-scale delivery platforms. The Company recently announced positive topline results from its Phase 2 study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy in untreated acute myeloid leukaemia, including a statistically significant improvement in complete remission rate and a reduction in 30-day and 60-day mortality. CPX-351 is one of a pipeline of investigational cancer therapies developed using Celator's CombiPlex drug-ratio technology. Celator also has an agreement with the National Cancer Institute's Nanotechnology Characterization Laboratory (NCL) whereby the NCL selected the Company's hydrophobic docetaxel prodrug nanoparticle formulation for intensive physical characterization, in-vitro studies, and in-vivo pharmacology and toxicology protocols to support an eventual investigational new drug (IND) filing with the US Food and Drug Administration.
Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world.
Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer.